Volume 137, Issue 3, Pages e1 (September 2009)

Slides:



Advertisements
Similar presentations
Increased Levels of Arginase in Patients With Acute Hepatitis B Suppress Antiviral T Cells Elena Sandalova, Diletta Laccabue, Carolina Boni, Tsunamasa.
Advertisements

Volume 143, Issue 3, Pages e1 (September 2012)
Volume 149, Issue 6, Pages (November 2015)
Volume 139, Issue 6, Pages e2 (December 2010)
Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis 
Volume 131, Issue 2, Pages (August 2006)
Covering the Cover Gastroenterology
Volume 149, Issue 6, Pages (November 2015)
Volume 140, Issue 3, Pages e3 (March 2011)
Effectiveness of Hepatitis B Treatment in Clinical Practice
Volume 153, Issue 4, Pages (October 2017)
Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and Ribavirin  Jean–François Rossignol, Asem Elfert,
Roberts Brown, Jean C. Emond  Gastroenterology 
Ira J. Fox, Stephen C. Strom  Gastroenterology 
Unusual Case of an Upset Stomach
Volume 133, Issue 5, Pages (November 2007)
Volume 153, Issue 3, Pages e16-e17 (September 2017)
Volume 135, Issue 4, Pages (October 2008)
American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive.
A Historical Perspective on Clinical Advances in Pancreatic Diseases
Volume 150, Issue 4, Pages (April 2016)
Volume 137, Issue 2, Pages (August 2009)
Volume 155, Issue 5, Pages e2 (November 2018)
Jean-Michel Pawlotsky  Gastroenterology 
Volume 146, Issue 7, Pages e3 (June 2014)
Virologic Response to Therapy Increases Health-Related Quality of Life for Patients With Chronic Hepatitis B  Jeong Han Kim, So Young Kwon, Young Sok.
Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans With Chronic Hepatitis C  Pamela S. Belperio, Elizabeth.
Volume 138, Issue 1, Pages (January 2010)
Volume 139, Issue 4, Pages e2 (October 2010)
A. Sidney Barritt, Michael W. Fried  Gastroenterology 
The Combination of Simeprevir and Sofosbuvir Is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients With Hepatitis C–Related.
Impact of New Hepatitis C Treatments in Different Regions of the World
Volume 142, Issue 6, Pages (May 2012)
Laura Rotundo, Sushil Ahlawat  Gastroenterology 
Efficacy of Linaclotide for Patients With Chronic Constipation
Volume 139, Issue 1, Pages e4 (July 2010)
Covering the Cover Gastroenterology
Rafael Esteban, Maria Buti  Gastroenterology 
Volume 140, Issue 7, Pages (June 2011)
Volume 145, Issue 6, Pages e5 (December 2013)
Ashwin N. Ananthakrishnan, David Lieberman  Gastroenterology 
Lisa I. Backus, Derek B. Boothroyd, Barbara R
Volume 148, Issue 3, Pages (March 2015)
Volume 137, Issue 6, Pages (December 2009)
Genetic Factors and Hepatitis C Virus Infection
Volume 136, Issue 7, Pages e4 (June 2009)
Yoshitaka Nishikawa, Takaki Sakurai, Shin’ichi Miyamoto 
Jeremy P. Dwyer, Patrick Hosking, John Lubel  Gastroenterology 
Volume 149, Issue 6, Pages (November 2015)
Volume 138, Issue 2, Pages (February 2010)
Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C  Gowtham A. Rao, Prashant K. Pandya  Gastroenterology 
Covering the Cover Gastroenterology
The Dawning of a New Editorial Board for Gastroenterology
Volume 143, Issue 3, Pages e1 (September 2012)
Secondary Prophylaxis of Hepatic Encephalopathy: An Open-Label Randomized Controlled Trial of Lactulose Versus Placebo  Barjesh Chander Sharma, Praveen.
Volume 156, Issue 1, Pages 7-10 (January 2019)
Alessio Aghemo, Maria Francesca Donato  Gastroenterology 
An Unusual Hepatic Mass With Mixed Cystic-Solid Components in a Woman
Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection  Harald Farnik, Christian M. Lange,
A 27-Year-Old Woman With Constipation: Diagnosis and Treatment
Volume 139, Issue 6, Pages e1 (December 2010)
Volume 134, Issue 7, Pages (June 2008)
A Necrotic Liver Mass Gastroenterology
Electronic Clinical Challenges and Images in GI
Volume 139, Issue 6, Pages e2 (December 2010)
Controversies in Liver Transplantation for Hepatitis C
A Female Patient With Persistent Epigastric Pain for 1 Week
Fasiha Kanwal, Tuyen Hoang, Timothy Chrusciel, Jennifer R
Abnormal Gastrointestinal Imaging in a Patient With Dyspepsia
A Rare Tumor of the Liver With a Sudden Presentation
Presentation transcript:

Volume 137, Issue 3, Pages 873-884.e1 (September 2009) Decline in Male Sexual Desire, Function, and Satisfaction During and After Antiviral Therapy for Chronic Hepatitis C  Lorna M. Dove, Raymond C. Rosen, Darmendra Ramcharran, Abdus S. Wahed, Steven H. Belle, Robert S. Brown, Jay H. Hoofnagle  Gastroenterology  Volume 137, Issue 3, Pages 873-884.e1 (September 2009) DOI: 10.1053/j.gastro.2009.05.060 Copyright © 2009 AGA Institute Terms and Conditions

Figure 1 Pretreatment sexual desire, function, and satisfaction by race. (A) Impairment in sexual desire. (B) Erectile dysfunction. (C) Ejaculatory dysfunction. (D) Global dissatisfaction with sex life. Gastroenterology 2009 137, 873-884.e1DOI: (10.1053/j.gastro.2009.05.060) Copyright © 2009 AGA Institute Terms and Conditions

Figure 2 Estimated percentage of no, mild, moderate, or severe impairment in the 5 components of sexual health before, during, and after peginterferon and ribavirin therapy. Results of questionnaires administered before therapy (time 0), at 4, 12, and 24 weeks in all patients, and at 48 weeks in virological responders. During follow-up, questionnaires were administered 24 weeks after stopping treatment, which was at week 48 for 6-month virological nonresponders (NR) and week 72 for virological responders (R). (A) Impairment in sexual desire. (B) Erectile dysfunction. (C) Ejaculatory dysfunction. (D) Global satisfaction with sex life. (E) Change in sex life (better, the same, or worse). Gastroenterology 2009 137, 873-884.e1DOI: (10.1053/j.gastro.2009.05.060) Copyright © 2009 AGA Institute Terms and Conditions

Figure 3 Impairment in sexual health during and after therapy. The solid line at 1 indicates the reference comparison (the pretreatment assessment). A proportional odds ratio and a 95% CI exceeding and not including 1 indicates significant impairment in the sexual health component compared with baseline. ^Posttreatment follow-up assessment. (A) Among participants undergoing 48 weeks of therapy. (B) Among participants undergoing only 24 weeks of therapy. Gastroenterology 2009 137, 873-884.e1DOI: (10.1053/j.gastro.2009.05.060) Copyright © 2009 AGA Institute Terms and Conditions